Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin

Hepatology Research

Volumn 39, Issue 4, 2009, Pages 346-354

  Kawamura, Yusuke ^a   Ikeda, Kenji ^a   Hirakawa, Miharu ^a   Hosaka, Tetsuya ^a   Kobayashi, Masahiro ^a   Saitoh, Satoshi ^a   Yatsuji, Hiromi ^a   Sezaki, Hitomi ^a   Akuta, Norio ^a   Suzuki, Fumitaka ^a   Suzuki, Yoshiyuki ^a   Arase, Yasuji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Hepatocellular carcinoma; Platinum analogue; Transcatheter arterial chemoembolization; Unresponsive

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIRUBICIN; IODINATED POPPYSEED OIL; LIPIODOL ULTRAFLUIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FEVER; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; VOMITING;

EID: 63649156187     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00466.x     Document Type: Article

References (24)

1. The Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Cancer 1987; 60: 1400-11.
2. The Liver Cancer Study Group of Japan. Primary liver cancer in Japan: clinicopathological features and results of surgical treatment. Ann Surg 1990; 211: 277-87.
3. Wheeler PG, Melia W, Dubbins P et al. Non-operative arterial embolization in primary liver tumours. Br Med J 1979; 2: 242-4.
4. Chuang VP, Wallace S. Hepatic arterial embolization in the treatment of hepatic neoplasms. Radiology 1981; 140: 51-8.
5. Okamura J, Horikawa S, Fujiyama T et al. An appraisal of transcatheter arterial infusion of chemotherapeutic agent for hepatic malignancies. World J Surg 1982; 6: 352-7.
6. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148: 397-401.
7. Lin DY, Liaw YF, Lee TY, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: A randomized controlled trial. Gastroenterology 1988; 94: 453-6.
8. Ikeda K, Kumada H, Saitoh S, Arase Y, Chayama K. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. Cancer 1991; 68: 2150-4.
9. Llovet JM, Real MI, Montaña X et al. Barcelona Liver cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002; 359: 1734-9.
10. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71.
11. Homma H, Mezawa S, Doi T et al. A comparative randomized trial of intermittent intrahepatic arterial carboplatin-versus doxorubicin-lipiodol emulsion in advanced hepatocellular carcinoma (stage IV). Hepatogastroenterology 2004; 51: 1135-9.
12. Shibata J, Fujiyama S, Sato T, Kishimoto S, Fukushima S, Nakano M. Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. Cancer 1989; 64: 1586-94.
13. Sasaki Y, Imaoka S, Kasugai H et al. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 1987; 60: 1194-203.
14. Imaoka S, Sasaki Y, Shibata T et al. A pre-operative chemoembolization therapy using lipiodol, cisplatin and gelatin sponge for hepatocellular carcinoma. Cancer Chemother Pharmacol 1989; 23: S126-8.
15. Yamamoto K, Shimizu T, Narabayashi I. Intraarterial infusion chemotherapy with lipiodol-CDDP suspension for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2000; 23: 26-39.
16. Maeda S, Shibata J, Fujiyama S et al. Long-term follow-up of hepatic arterial chemoembolization with cisplatin suspended in iodized oil for hepatocellular carcinoma. Hepatogastroenterology 2003; 50: 809-13.
17. Ikeda M, Maeda S, Shibata J et al. Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology 2004; 66: 24-31.
18. Ando E, Tanaka M, Yamashita F et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: Analysis of 48 cases. Cancer 2002; 95: 588-95.
19. Kaneko S, Urabe T, Kobayashi K. Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. Oncology 2002; 62: 69-73.
20. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
21. Hatanaka K, Kudo M, Fukunaga T et al. Clinical characteristics of NonBNonC-HCC: Comparison with HBV and HCV related HCC. Intervirology 2007; 50: 24-31.
22. Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: An analysis of the literature. Ann Oncol 1998; 9: 13-21. Review.
23. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17: 409-22. Review.
24. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48 (Suppl 1): S20-37. Review.